Tazemetostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Inclusion Criteria

• Histologically confirmed peripheral T-cell lymphomas (PTCL) with allowed subtypes listed below as per the revised World Health Organization 2022 classification: PTCL subtypes allowed * PTCL-not otherwise specified (not otherwise specified [NOS]) * Nodal T-follicular helper cell lymphoma - angioimmunoblastic type, follicular type, or NOS * Anaplastic Large Cell Lymphoma (ALK+) * Anaplastic Large Cell Lymphoma (ALK-) * Enteropathy-associated T-cell lymphoma * Monomorphic epitheliotropic intestinal T-cell lymphoma * Hepatosplenic T-cell lymphoma * Subcutaneous panniculitis-like T-cell lymphoma * Adult T-cell leukemia / lymphoma - lymphomatous, acute, or unfavorable chronic subtypes * Extra-nodal natural killer (NK)/T-cell lymphoma
• Patients must have relapsed or refractory disease. * Relapsed disease is defined when a patient progressed (> 3 months) after achieving CR with a previous treatment * Refractory disease is defined when a patient failed to achieve a CR or PR after a previous treatment
• Patients received at least 1 prior therapy for PTCL
• At least one bi-dimensionally measurable nodal lesion, defined as ≥ 1.5 cm in its longest dimension, or one bidimensionally measurable extranodal lesion, defined as ≥ 1.0 cm in its longest diameter on fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) scan as defined by response criteria for PTCL
• Age ≥ 18
• Patients with hepatitis C can be included if they have completed therapy for hepatitis C with undetectable viral load
• Patients with hepatitis B can be included if they are on suppressive therapy for hepatitis B infection and with no detectable viral load
• Patients with HIV can be included if they are on appropriate antiretroviral therapy, there is no interaction with the study drug, a CD4+ T-cell counts ≥ 350 cells/µL and no detectable viral load
• No more than moderate hepatic impairment per National Cancer Institute (NCI) Organ Dysfunction Working Group (ODWG) criteria
• Total bilirubin ≤ 3 X upper limit of normal (ULN) (unless attributed to disease involvement) (Note: transfusions and growth factors allowed during screening; however, transfusion-dependency defined as requiring blood products ≥once per week not allowed)
• Aspartate aminotransferase (AST) ≤ ULN (unless attributed to fatty liver or disease involvement) (unless attributed to disease involvement) (Note: transfusions and growth factors allowed during screening; however, transfusion-dependency defined as requiring blood products ≥ once per week not allowed)
• Creatinine clearance (CrCl) > 30ml/min using Cockroft-Gault, based on actual weight (unless attributed to disease involvement) (Note: transfusions and growth factors allowed during screening; however, transfusion-dependency defined as requiring blood products ≥ once per week not allowed)
• Absolute neutrophil count (ANC) ≥ 1,000/µL (unless attributed to disease involvement) (Note: transfusions and growth factors allowed during screening; however, transfusion-dependency defined as requiring blood products ≥ once per week not allowed)
• Platelet count ≥ 75,000/ µL (unless attributed to disease involvement) (Note: transfusions and growth factors allowed during screening; however, transfusion-dependency defined as requiring blood products ≥ once per week not allowed)
• Hemoglobin ≥ 8.0 g/dl (unless attributed to disease involvement) (Note: transfusions and growth factors allowed during screening; however, transfusion-dependency defined as requiring blood products ≥ once per week not allowed)
• Left ventricular ejection fraction (LVEF) defined by multiple-gated acquisition (MUGA) scan or echocardiogram within the institutional limits of normal
• Eastern Cooperative Oncology Group performance status of 0, 1, or 2
• A negative urine or serum pregnancy test is required for all women of childbearing potential within 1 week prior to enrolling on this trial and within 3 days of first dose of study drug. Note: Urine pregnancy tests that cannot be confirmed as negative require a confirmatory negative serum pregnancy test Non-childbearing potential is defined as: * Postmenopausal: Defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, FSH measurements indicating post-menopausal status must be documented in patient’s medical history. * Permanently sterile: Documented permanent sterilization e.g., hysterectomy, bilateral salpingectomy and bilateral oophorectomy
• If female of childbearing potential, subject must not be pregnant or be breastfeeding and is required to have a negative urine or serum pregnancy test within 3 days prior to the first dose of study drug. In addition, females of childbearing potential must either practice complete abstinence or agree to use two effective methods of contraception simultaneously, beginning ≥ 28 days prior to start of tazemetostat, during tazemetostat treatment, and for at least 6 months after final dose of tazemetostat
• Male subjects must either practice complete abstinence or agree to use a latex or synthetic condom during any sexual contact with a female of childbearing potential, from first dose of tazemetostat, during study treatment including dose interruptions, and for 3 months after last dose of tazemetostat. This applies even to males who have undergone successful vasectomy with medically confirmed azoospermia
• Willing and able to participate in all required evaluations and procedures in this study protocol including receiving intravenous administration of investigational product and being admitted, when required, for at least 24 hours during investigational product administration

Exclusion Criteria

• Current evidence of central nervous system involvement
• Completion of an autologous hematopoietic stem cell transplantation within 3 months prior to first dose of study drug
• Prior allogeneic stem cell transplant within 6 months. The patient should not have any active graft versus host (GVH) or should be on immune suppressive agents
• Completion of treatment with any radiotherapy, chemotherapy, antibody, immunoconjugates and/or another investigational drug ≤ 4 weeks (or 5 half-lives of the drug, whichever is shorter) prior to first dose of study drug. Patients may be enrolled after a minimum of 2 weeks of radiation if radiation was for palliative intent
• Prior therapy with an EZH2 inhibitor
• Inability to swallow and retain oral medications
• Pregnant women are excluded from this study
• Any active, concurrent, significant illness or disease (other underlying lymphoma) or clinically significant findings including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the patient from participation in the study such as: * Active infection requiring systemic therapy ≤10 days before the first dose of study drug; * Unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association [NYHA] II, III, IV;), myocardial infarction ≤ 6 months prior to first study drug, uncontrolled cardiac arrhythmia e.g., atrial fibrillation/flutter, cerebrovascular accidents ≤6 months before first dose of study drug * Any severe or uncontrolled other disease or condition which might increase the risk associated with study participation
• Vaccination with live, attenuated vaccines within 28 days prior to the first dose of study medication
• Receiving systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents). The use of inhaled corticosteroids is permitted
• Corticosteroids ≥ 10 mg of prednisone within the last 7 days
• Has had a solid organ transplant within the last 3 years. Note: Patients who have had a solid organ transplant > 3 years ago are eligible if there are no signs/symptoms of graft versus host disease (GvHD) and off immunosuppressive medications as per above
• Any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN)
• Any prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL) or B-cell acute lymphoblastic leukemia (B-ALL)
• Patients with the following subtypes of lymphoma: * T-cell prolymphocytic leukemia * T-large granular lymphocytic leukemia * NK-large granular lymphocytic leukemia * Aggressive NK-cell leukemia * Breast implant–associated anaplastic large-cell lymphoma
• Any other malignancy known to be active, with the exception of * Cervical carcinoma of stage 1B or less * Non-invasive basal cell or squamous cell skin carcinoma * Non-invasive, superficial bladder cancer * Prostate cancer with a current prostate specific antigen (PSA) level < 0.1 ng/mL * Any curable or localized cancer with a CR of > 2 years’ duration
• Any malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat
• Major surgery within 4 weeks before the first dose of study intervention. Note: Minor surgery (eg, minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 3 weeks prior to enrollment